GlassScriptPhysician profile
Jessa P Perry
NPI 1023528361
$519.92
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $503 · 2022: $17.11.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $150.14 | 2021 | |
| Lilly USA, LLC | $76.58 | 2021 | |
| Esperion Therapeutics, INC. | $70.04 | 2021 | |
| Novo Nordisk INC | $55.50 | 2021 | |
| Abbvie INC. | $48.62 | 2021-2022 | |
| Amarin Pharma, INC. | $35.20 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.74 | 2021 | |
| Eisai INC. | $19.16 | 2021 | |
| Abbott Laboratories | $16.80 | 2021 | |
| Merck Sharp & Dohme LLC | $14.21 | 2021 | |
| Clarus Therapeutics INC. | $13.93 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessa Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.